Oncogene-induced senescence and melanoma: Where do we stand?

Pigment Cell and Melanoma Research

Volumn 24, Issue 6, 2011, Pages 1107-1111

  Peeper, Daniel S ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Melanoma; Nevus; Senescence; Tumor suppression

Indexed keywords

CELL DEATH; CELL MATURATION; GENETIC ANALYSIS; HUMAN; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; MELANOMAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; NOTE; ONCOGENE; SENESCENCE;

ANIMALS; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MELANOMA; ONCOGENES; SKIN NEOPLASMS;

EID: 82055164279     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00933.x     Document Type: Note

References (53)

1. Acosta, J.C., O'Loghlen, A., Banito, A. et al. (2008). Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-1018.
2. Bandyopadhyay, D., Curry, J.L., Lin, Q., Richards, H.W., Chen, D., Hornsby, P.J., Timchenko, N.A., and Medrano, E.E. (2007). Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi. Aging Cell 6, 577-591.
3. Bartkova, J., Hořejší, Z., Koed, K. et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870.
4. Bennecke, M., Kriegl, L., Bajbouj, M., Retzlaff, K., and Robine, S. (2010). Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 18, 135-146.
5. Bennett, D.C. (2003). Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22, 3063-3069.
6. Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A.H.F.M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., and Schmitt, C.A. (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665.
7. Campaner, S., Doni, M., Hydbring, P. et al. (2010). Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat. Cell Biol. 12, 54-59; sup pp 1-14.
8. Campisi, J. (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513-522.
9. Campisi, J., Andersen, J.K., Kapahi, P., and Melov, S. (2011). Cellular senescence: a link between cancer and age-related degenerative disease? Semin. Cancer Biol. doi:10.1016/j.semcancer.2011.09.001.
10. Ceol, C.J., Houvras, Y., Jane-Valbuena, J. et al. (2011). The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471, 513-517.
11. Chen, Z., Trotman, L.C., Shaffer, D. et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730.
12. Collado, M., and Serrano, M. (2010). Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 10, 51-57.
13. Collado, M., Gil, J., Efeyan, A. et al. (2005). Tumour biology: senescence in premalignant tumours. Nature 436, 642.
14. Coppé, J.-P., Patil, C.K., Rodier, F., Sun, Y., Muñoz, D.P., Goldstein, J., Nelson, P.S., Desprez, P.-Y., and Campisi, J. (2008). Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853-2868.
15. Coppé, J.-P., Rodier, F., Patil, C.K., Freund, A., Desprez, P.-Y., and Campisi, J. (2011). Tumor suppressor and aging biomarker p16INK4a induces cellular senescence without the associated inflammatory secretory phenotype. J. Biol. Chem. 286, 36396-36403.
16. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E., You, M.J., Depinho, R.A., McMahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
17. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
18. Denoyelle, C., Abou-Rjaily, G., Bezrookove, V. et al. (2006). Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat. Cell Biol. 8, 1053-1063.
19. Dhomen, N., Reis-Filho, J.S., Da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., and Marais, R. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294-303.
20. Di Micco, R., Sulli, G., Dobreva, M. et al. (2011). Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat. Cell Biol. 13, 292-302.
21. Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., and Pereira-Smith, O. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367.
22. Giuliano, S., Ohanna, M., Ballotti, R., and Bertolotto, C. (2011). Advances in melanoma senescence and potential clinical application. Pigment Cell Melanoma Res 24, 295-308.
23. Goel, V.K., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T., Westmoreland, S., Haluska, F.S., Hinds, P.W., and Haluska, F.G. (2009). Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 28, 2289-2298.
24. Gorgoulis, V.G., Vassiliou, L.-V.F., Karakaidos, P. et al. (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913.
25. Gray-Schopfer, V.C., Cheong, S.C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z.A., Marais, R., Wynford-Thomas, D., and Bennett, D.C. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496-505.
26. Gruis, N.A., van der Velden, P.A., Sandkuijl, L.A., Prins, D.E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., and Frants, R.R. (1995). Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat. Genet. 10, 351-353.
27. Haferkamp, S., Scurr, L.L., Becker, T.M., Frausto, M., Kefford, R.F., and Rizos, H. (2009). Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors. J. Invest. Dermatol. 129, 1983-1991.
28. Herbig, U., Ferreira, M., Condel, L., Carey, D., and Sedivy, J.M. (2006). Cellular senescence in aging primates. Science 311, 1257.
29. Jaskelioff, M., Muller, F.L., Paik, J.-H. et al. (2011). Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 469, 102-106.
30. Karreth, F.A., Tay, Y., Perna, D. et al. (2011). In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147, 382-395.
31. Kondoh, H., Lleonart, M.E., Gil, J., Wang, J., Degan, P., Peters, G., Martinez, D., Carnero, A., and Beach, D. (2005). Glycolytic enzymes can modulate cellular life span. Cancer Res. 65, 177-185.
32. Kuilman, T., Michaloglou, C., Vredeveld, L.C.W., Douma, S., van Doorn, R., Desmet, C.J., Aarden, L.A., Mooi, W.J., and Peeper, D.S. (2008). Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019-1031.
33. Kuilman, T., Michaloglou, C., Mooi, W.J., and Peeper, D.S. (2010). The essence of senescence. Genes Dev. 24, 2463-2479.
34. Lee, B.Y., Han, J.A., Im, J.S., Morrone, A., Johung, K., Goodwin, E.C., Kleijer, W.J., Dimaio, D., and Hwang, E.S. (2006). Senescence-associated β-galactosidase is lysosomal β-galactosidase. Aging Cell 5, 187-195.
35. Lin, H.-K., Chen, Z., Wang, G. et al. (2010). Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464, 374-379.
36. Michaloglou, C., Vredeveld, L., Soengas, M., Denoyelle, C., Kuilman, T., van der Horst, C., Majoor, D., Shay, J., Mooi, W., and Peeper, D. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
37. Mooi, W.J., and Peeper, D.S. (2006). Oncogene-induced cell senescence - halting on the road to cancer. N. Engl. J. Med. 355, 1037-1046.
38. Narita, M., Narita, M., Krizhanovsky, V., Nuñez, S., Chicas, A., Hearn, S.A., Myers, M.P., and Lowe, S.W. (2006). A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126, 503-514.
39. Ohanna, M., Giuliano, S., Bonet, C. et al. (2011). Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev. 25, 1245-1261.
40. Patton, E.E., Widlund, H.R., Kutok, J.L. et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249-254.
41. Pollock, P.M., Harper, U.L., Hansen, K.S. et al. (2003). High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19-20.
42. Prickett, T.D., Agrawal, N.S., Wei, X., Yates, K.E., Lin, J.C., Wunderlich, J.R., Cronin, J.C., Cruz, P., Rosenberg, S.A., and Samuels, Y. (2009). Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 41, 1127-1132.
43. Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., and Barbacid, M. (2010). A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63-73.
44. Roninson, I.B. (2003). Tumor cell senescence in cancer treatment. Cancer Res. 63, 2705-2715.
45. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602.
46. Sparmann, A. (2004). Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447-458.
47. Sviderskaya, E.V., Gray-Schopfer, V.C., Hill, S.P. et al. (2003). p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J. Natl Cancer Inst. 95, 723-732.
48. Tuveson, D.A., Shaw, A.T., Willis, N.A. et al. (2004). Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387.
49. Ventura, A., Kirsch, D.G., Mclaughlin, M.E., Tuveson, D.A., Grimm, J., Lintault, L., Newman, J., Reczek, E.E., Weissleder, R., and Jacks, T. (2007). Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665.
50. Wajapeyee, N., Serra, R., Zhu, X., Mahalingam, M., and Green, M. (2008). Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132, 363-374.
51. Wei, X., Walia, V., Lin, J.C. et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446.
52. Xue, W., Zender, L., Miething, C., Dickins, R.A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., and Lowe, S.W. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660.
53. Ye, X., Zerlanko, B., Kennedy, A., Banumathy, G., Zhang, R., and Adams, P. (2007). Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol. Cell 27, 183-196.